Journal
THORAX
Volume 70, Issue 4, Pages 376-378Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2013-204114
Keywords
-
Categories
Funding
- Astra Zeneca
- GlaxoSmithKline
- Novartis
- Medimmune
- HSC RD (NI)
- GlaxoSmithKline (PhD studentship)
- Wellcome Senior Clinical Fellowship
- National Institute for Health Research [NF-SI-0512-10018] Funding Source: researchfish
Ask authors/readers for more resources
Severe refractory asthma poses a substantial burden in terms of healthcare costs but relatively little is known about the factors which drive these costs. This study uses data from the British Thoracic Society Difficult Asthma Registry (n=596) to estimate direct healthcare treatment costs from an National Health Service perspective and examines factors that explain variations in costs. Annual mean treatment costs among severe refractory asthma patients were 2912 pound (SD 2212) pound to mu 4217 (SD 2449) pound. Significant predictors of costs were FEV1% predicted, location of care, maintenance oral corticosteroid treatment and body mass index. Treating individuals with severe refractory asthma presents a substantial cost to the health service.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available